Colorado Bill Would Shield Orphan Drugs From Price Caps
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Colorado legislature is advancing a bill for the second time in two years to exempt orphan drugs from pricing caps the state's Prescription Drug Affordability Board might pursue.
- The Prescription Drug Affordability Board is closely watched by other states, giving Colorado's orphan-drug carve-out potential national significance.
- Pharmaceutical companies and patient groups back the bill, arguing patients could lose access to treatments if manufacturers halt sales in the state.
- Opponents contend the exemption would sweep in many big-selling medicines for common conditions that also carry orphan designations thanks to regulatory endorsements.
- Consumer advocates warn the legislation would raise the risk that countless patients struggle to pay for medicines and preserve drug company profits at taxpayer expense during state budgetary strain.
Why it matters: If enacted, the carve-out would let drug companies shield bestsellers for common conditions that also carry orphan designations from Colorado's affordability review—a board closely watched by other states. Consumer advocates warn the shift would preserve pharma profits at taxpayer expense during a state budget crunch, potentially making the precedent far broader than its rare-disease label suggests.
